NCT04350164View on ClinicalTrials.gov

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

April 1, 2012

Primary Completion Date

December 27, 2019

Study Completion Date

June 30, 2020

Conditions
Wiskott-Aldrich Syndrome
Interventions
DRUG

Romiplostim

romiplostim once weekly subcutaneously at an initial dose of 8-9 µg/kg per week for at least 1 month to 1 year.

Trial Locations (1)

117997

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER

NCT04350164 - Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome. | Biotech Hunter | Biotech Hunter